研究报告 Research Report 28 Aug 2025 医脉通 Medlive Technology (2192 HK) 25H1 业绩符合预期，应用 AI 技术提升平台能力 Performance meets expectations, applying AI technology to enhance platform capabilities [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$14.07 目标价 HK$15.00 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$10.33bn / US$1.33bn 日交易额 (3 个月均值) US$6.90mn 发行股票数目 734.26mn 自由流通股 (%) 26% 1 年股价最高最低值 HK$17.04-HK$7.20 注：现价 HK$14.07 为 2025 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][7]. Core Insights - The company is a leader in the medical digital marketing sector, leveraging 29 years of data assets to create a unique AI+medical platform. It has over 7 million registered users, with 2.65 million monthly active users, providing a strong foundation for value-added services to pharmaceutical companies and patients [1][12]. - The digital marketing landscape is rapidly expanding, with the market size exceeding 3 billion RMB in 2023 and a CAGR of 33.5% from 2019 to 2023. The shift towards digital marketing is driven by the need for compliance and efficiency in the medical field [2][58]. - The company has successfully monetized its large physician user base, achieving a compound annual growth rate (CAGR) of 36.8% in revenue from precision marketing and enterprise solutions from 2018 to 2024 [3][26]. Summary by Sections 1. Company Overview - The company has established itself as a leading medical information service platform, with a focus on enhancing user experience through a diverse range of products. It has developed AI products like MedAssister and MedSeeker, supported by a vast database of medical literature [1][12]. - The user base includes over 4 million registered physicians, achieving an 88% coverage rate among practicing physicians in China [12][68]. 2. Digital Marketing Industry - The digital marketing sector is witnessing significant growth, with a market size of 3 billion RMB in 2023. The industry is characterized by a shift towards compliance and efficiency, making digital marketing a preferred choice for pharmaceutical companies [2][58]. - The company’s digital marketing solutions have shown a clear advantage over traditional methods, offering better compliance, cost-effectiveness, and time efficiency [2][45]. 3. AI Empowerment - The company is leveraging AI to enhance the effectiveness of its data assets, launching products that integrate extensive medical data to improve customer acquisition and content generation [4][66]. - The forecasted net profits for 2025, 2026, and 2027 are projected to be 322 million, 364 million, and 415 million RMB, respectively, with corresponding growth rates of 2.2%, 13.2%, and 13.8% [4][6]. 4. Financial Forecast and Valuation - The company’s revenue is expected to grow from 558 million RMB in 2024 to 1.092 billion RMB in 2027, with a CAGR of 35.5% from 2024 to 2027 [6][26]. - The projected P/E ratios for 2025, 2026, and 2027 are 26, 23, and 20, respectively, indicating a favorable valuation outlook [4][6].